Madrigal Pharmaceuticals Inc

MDGL

NASDAQ. Currency in USD

234.83 +171.03 ( +268.07% )

Real time prices: December 19

Market Cap.

4.02B

Beta (5Y monthly)

0.89 Price/Earnings

-

EPS (TTM)

-16.03

Forward Dividend

0.00 (0.00%)

Ex-Dividend Date

Volume

8.71M

1y Target Est.

152.58 Day's Range

191.49

236.39

52 Week's Range

57.15

236.39

Historical Summary

Performance

1 Month

222.57%

YTD

177.12%

1Y

202.77%

2Y

100.50%

41.63% ann.

3Y

164.48%

38.28% ann.

5Y

148.10%

19.93% ann.

EPS growth

1Y

-9.42%

2Y

-44.81%

25.72% ann.

3Y

-264.32%

-18.00% ann.

5Y

-531.10%

-33.95% ann.

10Y

53.69%

4.39% ann.

Share Buybacks

3 Months

-0.00%

6 Months

-0.00%

1Y

-2.79%

2Y

-10.71%

3Y

-10.95%

5Y

-38.17%

10Y

-886.81%

About Madrigal Pharmaceuticals Inc

Sector

Healthcare

Industry

Biotechnology

Website

https://www.madrigalpharma.com

Exchange

NASDAQ (XNAS)

Shares Outstanding

17.10M

Employees

71 Address

Four Tower Bridge, West Conshohocken, PA, United States, 19428

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Latest news

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced...
By Benzinga - 6 weeks ago

Why Madrigal Pharmaceuticals Stock Is Crushing It Today

The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.
By The Motley Fool - 6 weeks ago

MDGL 268.07%

Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday

U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here...
By Benzinga - 6 weeks ago

Tesla's Bouncing, but This Nasdaq Stock Tripled Monday Morning

Good news can come in different forms.
By The Motley Fool - 6 weeks ago

TSLA -0.24%

MDGL 268.07%

VKTX 73.88%

Tesla, Amazon, Madrigal Pharma, Pfizer, Synaptogenix: Why These 5 Stocks Are Drawing Investors' Attention Today

Major Wall Street indices had closed in the red on Friday in the wake of...
By Benzinga - 7 weeks ago

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage...
By GlobeNewswire Inc. - 7 weeks ago

MDGL 268.07%

2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter

These two healthcare stocks could deliver market-crushing gains by year's end.
By The Motley Fool - 13 weeks ago

MDGL 268.07%

AXSM -3.30%

Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon

NASH is a common disease, but there are no approved treatments for it. These two...
By The Motley Fool - 20 weeks ago

MDGL 268.07%

VKTX 73.88%